CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

Prostate cancer harboring BRCA1/2 mutations are often exceptionally sensitive to PARP inhibitors. However, genomic alterations in other DNA damage response genes have not been consistently predictive of clinical response to PARP inhibition. Here, we perform genome-wide CRISPR-Cas9 knockout screens i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsujino, Takuya, Takai, Tomoaki, Hinohara, Kunihiko, Gui, Fu, Tsutsumi, Takeshi, Bai, Xiao, Miao, Chenkui, Feng, Chao, Gui, Bin, Sztupinszki, Zsofia, Simoneau, Antoine, Xie, Ning, Fazli, Ladan, Dong, Xuesen, Azuma, Haruhito, Choudhury, Atish D., Mouw, Kent W., Szallasi, Zoltan, Zou, Lee, Kibel, Adam S., Jia, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845315/
https://www.ncbi.nlm.nih.gov/pubmed/36650183
http://dx.doi.org/10.1038/s41467-023-35880-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845315/
https://www.ncbi.nlm.nih.gov/pubmed/36650183
http://dx.doi.org/10.1038/s41467-023-35880-y

Ejemplares similares